Targeting S100A8/S100A9 induced MDSCs in inflammatory disorders

Principal investigators: Sven Hermann, Thomas Vogl
Project number: CRC 1450 C03
Project term: 01/2021–12/2028

Immune-regulatory mechanisms limiting immunological responses are promising new therapeutic targets for chronic inflammatory diseases. This project will investigate to what extent the tetrameric form of the alarmin S100A8/S100A9 modulates the regulatory phenotype of MDSCs via CD69 in experimental models of arthritis and inflammatory tumour microenvironment. Multiscale imaging methods will be used to localize and study the interaction of MDSCs, S100A8/S100A9 and activated leukocytes in mouse models of arthritis and tumour xenografts over time and to evaluate the therapeutic potential of modulating the MDSC phenotype in arthritis.

Team

Principal investigators

• Hermann, Sven, Priv.-Doz. Dr. med.
  European Institute for Molecular Imaging
• Vogl, Thomas, Prof. Dr. rer. nat.
  Institute of Immunology

Project members

• Bobrowski, Jan
  Institute of Immunology
• Czaijka, Wiktor
  European Institute for Molecular Imaging

Publications

The names of the principal investigators in our network have been bolded. Publications released prior to 2021, when funding for our network commenced, represent previous project-related work.